U.S. Department of Health and Human Services
Rebecca Brown

 Contact Info

Tel: 301-594-0609
Email: brownrebecca@mail.nih.gov

 Select Experience

  • Assistant Clinical InvestigatorNIDDK, NIH2012–2015
  • Senior FellowNIDDK, NIH2008–2012
  • FellowNICHD, NIH2005–2008
  • ResidentRainbow Babies and Children’s Hospital2002–2005
  • Lasker Tenure Track InvestigatorNIDDK, NIH2015-present
  • M.H.Sc.Duke University2011
  • M.D.Mayo Medical School2002

 Related Links


Rebecca J. Brown, M.D., M.H.Sc., Lasker Tenure Track Investigator

Lasker Tenure Track Investigator, Section on Translational Diabetes and Metabolic SyndromesDiabetes, Endocrinology, and Obesity Branch
  • Clinical Research


A selection of recent and significant publications can be viewed below.

Kassai A, Muniyappa R, Levenson AE, Walter MF, Abel BS, Ring M, Taylor SI, Biddinger SB, Skarulis MC, Gorden P, Brown RJ. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2016 Feb 22; 101 (2016 Feb 22; 101; 4):1790-7. [Full Text/Abstract]
Levenson AE, Haas ME, Miao J, Brown RJ, de Ferranti SD, Muniyappa R, Biddinger SB. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients. Endocrinology. 2016 Jan 29; 157 (157; 2016 Jan 29; 4):1421-1429. [Full Text/Abstract]
Cochran E, Brown RJ, Gorden P. Other Antibodies Resulting in Diabetes Mellitus: Type B Insulin Resistance and Insulin Autoimmune Syndrome. AACE Clin Case Rep. 2016 Jan 20; 2 (2; 3; 2016 Jan 20):e272-e275. [Full Text/Abstract]
Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2015 Oct 14; 9 (9; 2015 Oct 14; 1):1-10. [Full Text/Abstract]
Abel BS, Muniyappa R, Stratton P, Skarulis MC, Gorden P, Brown RJ. Effects of Recombinant Human Leptin (Metreleptin) on Nocturnal Luteinizing Hormone Secretion in Lipodystrophy Patients. Neuroendocrinology. 2015 Aug 25; 103 (3-4; 2015 Aug 25; 103):402-7. [Full Text/Abstract]
Brown RJ, Meehan CA, Gorden P. Leptin Does Not Mediate Hypertension Associated With Human Obesity. Cell. 2015 Jul 30; 162 (2015 Jul 30; 162; 3):465-6. [Full Text/Abstract]
Meehan CA, Cochran E, Mattingly M, Gorden P, Brown RJ. Mild Caloric Restriction Decreases Insulin Requirements in Patients With Type 2 Diabetes and Severe Insulin Resistance. Medicine (Baltimore). 2015 Jul; 94 (94; 2015 Jul; 30):e1160. [Full Text/Abstract]
Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, Goujard C, Vigouroux C, Gorden P. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2015 Apr 12; 57 (2015 Apr 12; 1; 57):1-21. [Full Text/Abstract]
Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015 Mar 3; 100 (2015 Mar 3; 100; 5):1802-1810. [Full Text/Abstract]
Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ. Lipid Regulation in Lipodystrophy Versus the Obesity-Associated Metabolic Syndrome: The Dissociation of HDL-C and Triglycerides. J Clin Endocrinol Metab. 2014 Jun 13; 99 (99; 2014 Jun 13; 9):E1676-80. [Full Text/Abstract]
Payne F, Lim K, Girousse A, Brown RJ, Kory N, Robbins A, Xue Y, Sleigh A, Cochran E, Adams C, Dev Borman A, Russel-Jones D, Gorden P, Semple RK, Saudek V, O'Rahilly S, Walther TC, Barroso I, Savage DB. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad Sci U S A. 2014 Jun 17; 111 (111; 2014 Jun 17; 24):8901-6. [Full Text/Abstract]
Brown RJ, Yanovski JA. Estimation of insulin sensitivity in children: methods, measures and controversies. Pediatr Diabetes. 2014 May; 15 (2014 May; 15; 3):151-61. [Full Text/Abstract]
Muniyappa R, Brown RJ, Mari A, Joseph J, Warren MA, Cochran EK, Skarulis MC, Gorden P. Effects of Leptin Replacement Therapy on Pancreatic β-Cell Function in Patients With Lipodystrophy. Diabetes Care. 2014 Apr; 37 (37; 4; 2014 Apr):1101-7. [Full Text/Abstract]
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014 Mar; 37 (2014 Mar; 37; 3):666-70. [Full Text/Abstract]
Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI. Challenging recruitment of youth with type 2 diabetes into clinical trials. J Adolesc Health. 2014 Mar; 54 (2014 Mar; 3; 54):247-54. [Full Text/Abstract]
Brown RJ, Cochran E, Gorden P. Metreleptin improves blood glucose in patients with insulin receptor mutations. J Clin Endocrinol Metab. 2013 Nov; 98 (98; 2013 Nov; 11):E1749-56. [Full Text/Abstract]
Rother KI, Brown RJ. Novel Forms of Lipodystrophy: Why should we care?. Diabetes Care. 2013 Aug; 36 (8; 2013 Aug; 36):2142-5. [Full Text/Abstract]
Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013 Jul; 59 (59; 2013 Jul; 1):131-7. [Full Text/Abstract]
Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19 (19; 2013 Jan-Feb; 1):107-16. [Full Text/Abstract]
Sylvetsky AC, Welsh JA, Brown RJ, Vos MB. Low-calorie sweetener consumption is increasing in the United States. Am J Clin Nutr. 2012 Sep; 96 (2012 Sep; 3; 96):640-6. [Full Text/Abstract]
Gorden P, Zadeh ES, Cochran E, Brown RJ. Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance. Endocr Pract. 2012 Sep-Oct; 18 (2012 Sep-Oct; 5; 18):763-71. [Full Text/Abstract]
Brown RJ, Rother KI. Non-nutritive sweeteners and their role in the gastrointestinal tract. J Clin Endocrinol Metab. 2012 Aug; 97 (2012 Aug; 8; 97):2597-605. [Full Text/Abstract]
Foreyt J, Kleinman R, Brown RJ, Lindstrom R. The use of low-calorie sweeteners by children: implications for weight management. J Nutr. 2012 Jun; 142 (2012 Jun; 6; 142):1155S-62S. [Full Text/Abstract]
Brown RJ, Walter M, Rother KI. Effects of diet soda on gut hormones in youths with diabetes. Diabetes Care. 2012 May; 35 (2012 May; 35; 5):959-64. [Full Text/Abstract]
Sylvetsky A, Rother KI, Brown R. Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions. Pediatr Clin North Am. 2011 Dec; 58 (6; 58; 2011 Dec):1467-80, xi. [Full Text/Abstract]
Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011 Apr; 13 (2011 Apr; 4; 13):457-60. [Full Text/Abstract]
Brown RJ, Walter M, Rother KI. Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. Diabetes Care. 2009 Dec; 32 (32; 12; 2009 Dec):2184-6. [Full Text/Abstract]
Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care. 2009 Jul; 32 (32; 7; 2009 Jul):1250-5. [Full Text/Abstract]
Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, Cowen EW. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol. 2009 Jan; 145 (145; 2009 Jan; 1):63-6. [Full Text/Abstract]
Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care. 2008 Jul; 31 (7; 2008 Jul; 31):1403-4. [Full Text/Abstract]